Abstracts tagged "Behcet’s syndrome and Disease Activity"

Abstract Number: 3047 • 2015 ACR/ARHP Annual Meeting
Association Between Red Blood Cell Distribution Width and Disease Activity in Behcet’s Disease
Byung-Woo Yoo, Jason Jungsik Song, Sang-Won Lee, Yong-Beom Park, Soo-Kon Lee and Sung Soo Ahn, Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Behcet's disease (BD) is a chronic systemic inflammatory disorder characterized by recurrent oral aphtae and other systemic involvement. Red blood cell distribution width (RDW)…
Abstract Number: 3053 • 2015 ACR/ARHP Annual Meeting
Patients Treated for Behcet Syndrome in the US Have Higher Disease Activity Scores at Presentation If They Fulfill ISG Criteria and If They Are Females, However Have Less Severe Disease Overall
Yusuf Yazici, Hannah Bernstein and Christopher Swearingen, Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Diagnosis of Behcet’s syndrome (BS) is based on clinical signs and symptoms, without the use laboratory or imaging tests and the most commonly used…
Abstract Number: 2615 • 2013 ACR/ARHP Annual Meeting
Serum Beta 2 Microglobulin and Its Association With Disease Activity in Patients With Behcet’s Disease
Meltem Alkan Melikoglu¹ and Mehmet Melikoglu², ¹Rheumatology, Ataturk University Faculty of Medicine, Erzurum, Turkey, ²Dermatology, Health Ministry Erzurum Regional Training and Research Hospital, Dermatology, Erzurum, Turkey
Background/Purpose: β2-microglobulin (β2M) is a low-molecular weight protein, that is a constant component of human leukocyte antigen (HLA), which is secreted from all nucleated cells.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].